Vaccines in the public eye

Article metrics

Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1

References

  1. 1

    Diamond, J. Guns, Germs and Steel (W.W. Norton & Company, New York, 1999).

  2. 2

    Potter, C.W. in Textbook of Influenza (eds Nicholson, K.G., Webster, R.G. & Hay, A.J.) 3–18 (Blackwell Science, Oxford, 1998).

  3. 3

    Donnelly, C.A. et al. Lancet Infect. Dis. 4, 672–683 (2004).

  4. 4

    World Health Organization. Summary table of SARS cases by country, 1 November 2002 – 7 August 2003 <http://www.who.int/csr/sars/country/en/country2003_08_15.pdf> (2003).

  5. 5

    Knobler, S.L., Mack, A., Mahmoud, A. & Lemon, S.M. (eds). The threat of pandemic influenza: are we ready? Workshop summary report by the Board on Global Health, Institute of Medicine. (National Academies Press, Washington, DC, 2004).

  6. 6

    Weiss, R.A. & McMichael, A.J. Nat. Med. 10, S70–S76 (2004).

  7. 7

    Kremer, M. in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue (eds Kaul, I., Goulven, K. & Schnupf, M.) 37–42 (UNDP/ODS, New York, 2002).

  8. 8

    Kremer, M. & Glennerster, R. A World Bank vaccine commitment. Brookings Institution Policy Brief #57 <http://www.brookings.edu/comm/policybriefs/pb57.htm> (2000).

  9. 9

    Plotkin, S.L. & Plotkin, S.A. in Vaccines (eds Plotkin, S.A. & Orenstein W.A.) 1–11 (Saunders, Philadelphia, 1999).

  10. 10

    Slovic, P. Science 236, 280 (1987)

  11. 11

    Greenberg, S. South. Med. J. 93, 763–767 (2000).

  12. 12

    Hennock, E.P. Soc. Hist. Med. 11, 49–71 (1998).

  13. 13

    Gellin, B.G., Maibach, E.W. & Marcuse, E.K. Pediatrics 106, 1097–1102 (2000).

  14. 14

    Mieczkowski, T.A. & Wilson, S.A. Vaccine 18, 1383–1392 (2002).

  15. 15

    Liau, A. & Zimet, G.D. AIDS Care 13, 643–650 (2001)

  16. 16

    Liau, A. & Zimet, G.D. Int. J. STD AIDS 11, 445–450 (2000)

  17. 17

    Zimet, G.D., Blythe, M.J. & Fortenberry, J.D. Int. J. STD AIDS 11, 143–149 (2000).

  18. 18

    Honkanen, P.O., Keistinen, T. & Kivela, S.L. Public Health 110, 163–168 (1996).

  19. 19

    Zimet, G.D., Fortenberry, J.D. & Blythe, M.J. J. Pediatr. Psychol. 24, 67–75 (1999).

  20. 20

    Webb, P.M., Zimet, G.D., Mays, R. & Fortenberry, J.D. J. Adoles. Health 25, 320–322 (1999).

  21. 21

    Liau, A, Zimet, G.D. & Fortenberry, J.D. Sex. Transm. Dis. 25, 76–81 (1998).

  22. 22

    Nichol, K.L. & Zimmerman, R. Arch. Intern. Med. 161, 2702–2708 (2001).

  23. 23

    Nichol, K.L., Lofgren, R.P. & Gapinski, J. Arch. Intern. Med. 152, 106–10 (1992).

  24. 24

    McPhillips, H.A., Davis, R.L., Marcuse, E.K. & Taylor, J.A. Arch. Pediatr. Adolesc. Med. 155:1051–1056 (2001).

  25. 25

    Fiebach, N.H. & Viscoli, C.M. Am. J. Med. 91, 393–400 (1991).

  26. 26

    Mezaros J.R. et al. J. Clin. Epidemiol. 49, 697–703 (1996).

  27. 27

    Ritvo, P. et al. J. Immune Based Ther. Vaccines 1, 3 (2003).

  28. 28

    Abraham, J. Lancet 360, 1498–1502 (2002).

  29. 29

    Keller-Stanislawski, B. Vaccine 20, S45–S46 (2002).

  30. 30

    Hernan, M.A., Jick, S.S., Olek, M.J. & Jick, H. Neurology 63, 838–842 (2004).

  31. 31

    Immunization Safety Committee. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders (National Academy Press, Washington, DC, 2002).

  32. 32

    DeStefano, F. et al. Arch. Neurol. 60, 504–509 (2003).

  33. 33

    Ascherio, A. et al. N. Engl. J. Med. 344, 327–332 (2001).

  34. 34

    Confavreux, C., Suissa, S., Saddier, P., Bourdes, B. & Vukusic, S. N. Engl. J. Med. 344, 319–326 (2001).

  35. 35

    Sadovnick, A.D. & Scheifele, D.W. Lancet 355, 549–550 (2000).

  36. 36

    World Health Organization Global Advisory Committee on Vaccine Safety. Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled “Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis” <http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/> (2004).

  37. 37

    Levy-Bruhl, D., Desenclos, J.C., Rebiere, I. & Drucker, J. Vaccine 20, 2065–2071 (2002).

  38. 38

    Touzé, E., Gout, O., Verdier-Taillefer, M.H., Lyon-Caen, O. & Alpérovitch, A. Rev. Neurol. 152, 242–246 (2000).

  39. 39

    Touzé, E., Fourrier, A., Rue-Fenouche, C., Rondé-Ousteau, V., Jeantaud, I. & Bé gaud, B. Neuroepidemiology 21, 180–186 (2002).

  40. 40

    Sturkenboom, M.C.J.M. et al. Pharmacoepidemiol. Drug Saf. 8, S170–S171 (1999).

  41. 41

    Cage, S. WHO: Islamic state in Nigeria will resume polio vaccinations in early July. Associated Press 30 June 2004.

  42. 42

    Qadir, A. India gears up for last mile of polio eradication but poor shun vaccine drops in eastern state. Associated Press 28 August 2004.

  43. 43

    Renn, O. Risk communication and social amplification of risk. In Communicating Risks to the Public: International Perspectives (eds. Kasperson, RE. & Stallen, P.M.) (Kluwer, Amsterdam, 1991).

  44. 44

    Powell, D. & Leiss, W. Mad Cows and Mother's Milk: The Peril of Poor Risk Communication (McGill-Queen's University Press, Montreal, 1997).

  45. 45

    UK Department of Health. Statistical Bulletin: NHS Immunization Statistics 2003-04 (UK Department of Health, London, 2004).

  46. 46

    Wakefield, A.J. et al. Lancet 351, 637–641 (1998).

  47. 47

    Murch, S.H., et al. Lancet 363(9411), 750 (2004).

  48. 48

    Ward, L. Minister outlines steps to boost image of MMR jabs. The Guardian. 21 February 2002.

  49. 49

    Jansen, V.A. et al. Science 301, 804 (2003).

  50. 50

    Krahn, M. et al. Vaccine 23, 1549–1558 (2005).

  51. 51

    Kremer, A. A Purchase Commitment for Vaccines. in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue. (ed. Kaul, I., le Goulven, K. & Schnupf, M.) 37–42 (UNDP/ODS, New York, 2002).

  52. 52

    Muraskin, W., Hotez, P. & Sachs, J. Vaccines for developing economies – who will pay? The Albert Sabin Vaccine Institute Colloquium at Cold Spring Harbor (The Albert B. Sabin Vaccine Institute, New Canaan, Connecticut, 2001).

  53. 53

    Horton, R. Lancet 364, 2071–2074 (2004).

  54. 54

    Hirschler, B. Chirac calls for global tax to fight AIDS. The Toronto Star. January 27, 2005.

  55. 55

    Ungchusak, K. et al. N. Eng. J. Med. 352, 333–3640 (2005).

  56. 56

    Alonso, P.L. et al. Lancet 364, 1411–1420 (2004).

  57. 57

    Harper, D.M. et al. Lancet 364, 1757–1765 (2004).

Download references

Acknowledgements

The authors want to acknowledge expert assistance from D. Levy-Bruhl (Départment des Maladies Infectieuses Institut de Veille Sanitaire) in the preparation of this manuscript, and M. Kremer (Department of Economics, Harvard University and the Brookings Institution) for helpful review and comments.

Author information

Correspondence to Paul Ritvo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ritvo, P., Wilson, K., Willms, D. et al. Vaccines in the public eye. Nat Med 11, S20–S24 (2005) doi:10.1038/nm1220

Download citation

Further reading